Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Assets (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Return on Assets for 9 consecutive years, with 0.74% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Assets fell 76.0% year-over-year to 0.74%, compared with a TTM value of 0.74% through Sep 2025, down 76.0%, and an annual FY2024 reading of 0.47%, down 62.0% over the prior year.
  • Return on Assets was 0.74% for Q3 2025 at Spero Therapeutics, up from 0.77% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.16% in Q4 2023 and bottomed at 1.48% in Q3 2022.
  • Average Return on Assets over 5 years is 0.45%, with a median of 0.56% recorded in 2021.
  • The sharpest move saw Return on Assets crashed -89bps in 2022, then skyrocketed 143bps in 2023.
  • Year by year, Return on Assets stood at 0.56% in 2021, then increased by 14bps to 0.48% in 2022, then surged by 134bps to 0.16% in 2023, then crashed by -442bps to 0.56% in 2024, then tumbled by -32bps to 0.74% in 2025.
  • Business Quant data shows Return on Assets for SPRO at 0.74% in Q3 2025, 0.77% in Q2 2025, and 0.75% in Q1 2025.